Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.55 |
| ▸ | LHCGR | P22888 | 8/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | FSHR | P23945 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037288 | 0.90 | LHCGR (0.70) | BRAFLHCGRTSHRFSHRMEN1 | |
| SCHEMBL27567548 | 0.88 | BRAF (0.54) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL4421622 | 0.85 | LHCGR (0.60) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL6217358 | 0.82 | LHCGR (0.57) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL4911478 | 0.82 | BRAF (0.72) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL4422658 | 0.82 | LHCGR (0.58) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL4422865 | 0.81 | LHCGR (0.54) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL4430436 | 0.81 | LHCGR (0.77) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL5024555 | 0.81 | LHCGR (0.55) | BRAFLHCGRTSHRPDE4APDE4B | |
| SCHEMBL5030974 | 0.80 | LHCGR (0.53) | BRAFLHCGRTSHRPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | BRAF 4474/4885LHCGR 13/4885TSHR 1000/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | BRAF 4242/4885LHCGR 10/4885TSHR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.